Average FVIII levels over time after AAV gene therapy. Median FVIII levels as determined by either OSA or estimated OSA by multiplying the available CSA values by 1.6, except for giroctocogene fitelparvovec for which only mean values reported. The blue rectangle indicates prophylactic FVIII or FVIII-equivalency achieved by current standards of care.